Trajenta (TRA-gen-ta), a new gliptin for type 2 diabetes
Reps will be promoting Trajenta (TRA-gen-ta), a new gliptin for type 2 diabetes.
Trajenta (linagliptin) is a "me-too"...similar to Onglyza (saxagliptin) and Januvia (sitagliptin). These prolong incretin activity to stimulate insulin and reduce glucagon release.
Trajenta's only real claim to fame is that it's approved for patients with mild to moderate renal impairment.